Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion

Abstract

Purpose:

To compare the effects of intravitreal ranibizumab injection and yellow (577 nm) subthreshold micropulse laser treatment in patients with macular edema following non-ischemic branch retinal vein occlusion.

Methods:

The medical records of 51 patients who underwent intravitreal ranibizumab (0.5 mg) injection or subthreshold micropulse laser for the treatment of macular edema due to branch retinal vein occlusion were retrospectively reviewed. Subthreshold micropulse laser was administered with a 10% duty cycle, 100 μm spot diameter, 200 ms exposure time. The patients received an injection or laser treatment at baseline and were, then, retreated as needed and were followed for 12 months. The mean best corrected visual acuity changes over the follow-up and the decrease in the mean central macular thickness were evaluated.

Results:

A total of 27 and 24 patients were assigned to intravitreal ranibizumab and subthreshold micropulse laser subgroups, respectively. The mean number of treatment was 3.81 of intravitreal ranibizumab group and 1.5 of subthreshold micropulse laser group (p < 0.05). The subgroups were similar with regard to the mean score of best corrected visual acuity at baseline, at 1, 6, and 12 months (p > 0.05). The decrease in the mean central macular thickness was significant in both intravitreal ranibizumab and subthreshold micropulse laser groups at 1, 6, and 12 months than that of values at baseline (p < 0.05). No new ocular or systemic adverse events were observed.

Conclusion:

Our study results showed that intravitreal ranibizumab or yellow subthreshold micropulse laser treatment for macular edema due to branch retinal vein occlusion was not found to be superior to each other for reducing macular thickness and increasing visual acuity for 1-year period. Based on these results, subthreshold micropulse laser may be a useful alternative approach in the treatment of macular edema secondary to branch retinal vein occlusion.

Keywords

Branch retinal vein occlusion macular edema ranibizumab subthreshold micropulse laser

Get full access to this article

View all access options for this article.

References

Rogers

McIntosh

Cheung

et al . The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313–319.

Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984; 98: 271–282.

Koss

Pfister

Rothweiler

et al . Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol 2012; 90: e98–e103.

Noma

Funatsu

Yamasaki

et al . Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005; 140: 256–261.

Campochiaro

Hafiz

Shah

et al . Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008; 16: 791–799.

Mitry

Bunce

Charteris

. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev 2013(1): CD009510.

Rabena

Pieramici

Castellarin

et al . Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007; 27(4): 419–425.

Roider

Michaud

Flotte

et al . Response of the retinal pigment epithelium to selective photocoagulation. Arch Ophthalmol 1992; 110(12): 1786–1792.

Roider

. Laser treatment of retinal diseases by subthreshold laser effects. Semin Ophthalmol 1999; 14(1): 19–26.

10.

Mainster

. Decreasing retinal photocoagulation damage: principles and techniques. Semin Ophthalmol 1999; 14(4): 200–209.

11.

Inagaki

Ohkoshi

Ohde

. Spectral-domain optical coherence tomography imaging of retinal changes after conventional multicolor laser, subthreshold micropulse diode laser, or pattern scanning laser therapy in Japanese with macular edema. Retina 2012; 32(8): 1592–1600.

12.

Scholz

Altay

Fauser

. A review of subthreshold micropulse laser for treatment of macular disorders. Adv Ther 2017; 34(7): 1528–1555.

13.

Hubschman

. A review of subthreshold micropulse laser and recent advances in retinal laser technology. Ophthalmol Ther 2017; 6: 1–6.

14.

Ferrara

Koizumi

Spaide

. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007; 144: 864–871.

15.

Shah

. Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: a pilot study. Eye 2011; 25: 239–244.

16.

Spaide

Chang

Klancnik

et al . Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009; 147: 298–306.

17.

Kokolaki

Georgalas

Koutsandrea

et al . Comparative analysis of the development of collateral vessels in macular edema due to branch retinal vein occlusion following grid laser or ranibizumab treatment. Clin Ophthalmol 2015; 9: 1519–1522.

18.

Campochiaro

Heier

Feiner

et al . Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010; 117: 1102–1112.

19.

Brown

Campochiaro

Bhisitkul

et al . Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594–1602.

20.

Pece

Isola

Piermarocchi

et al . Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. Br J Ophthalmol 2011; 95: 56–68.

21.

Parodi

Spasse

Iacono

et al . Subthreshold grid laser treatment of macular edema secondary to branch retinal vein occlusion with micropulse infrared (810 nanometer) diode laser. Ophthalmology 2006; 113(12): 2237–2242.

22.

Parodi

Iacono

Bandello

. Subthreshold grid laser versus intravitreal bevacizumab as second-line therapy for macular edema in branch retinal vein occlusion recurring after conventional grid laser treatment. Graefes Arch Clin Exp Ophthalmol 2015; 253(10): 1647–1651.

23.

Inagaki

Ohkoshi

Ohde

et al . Subthreshold micropulse photocoagulation for persistent macular edema secondary to branch retinal vein occlusion including best-corrected visual acuity greater than 20/40. J Ophthalmol 2014; 2014: 251–257.

24.

Yadav

Jayadev

Mohan

et al . Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome. Eye 2015; 29(2): 258–264.

25.

Kwon

Lee

Kwon

. The short-term efficacy of subthreshold micropulse yellow (577-nm) laser photocoagulation for diabetic macular edema. Korean J Ophthalmol 2014; 28(5): 379–385.

26.

Kim

Park

Kim

. Short-term efficacy of subthreshold micropulse yellow laser (577-nm) photocoagulation for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2015; 253(12): 2129–2135.